Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.

Ian E Krop, Lorenza Mittempergher, Joseph N Paulson, Fabrice Andre, Herve Bonnefoi, Sherene Loi, Sibylle Loibl, Richard D Gelber, Carmela Caballero, Rajith Bhaskaran, Christa Dreezen, Andrea R Menicucci, Rene Bernards, Laura J van 't Veer, Martine J Piccart

January 2024 JCO Precis Oncol

Synopsis of Social media discussions

Discussions highlight excitement about the study's potential for personalized therapy, with phrases like 'benefit prediction' and references to the trial's significance, while also indicating interest in the gene signature approach. The tone suggests a recognition of the study's importance without overestimating its immediate clinical impact.

A
Agreement
 Moderate agreement

Most discussions acknowledge the potential of the 80-gene signature to predict benefits from pertuzumab, indicating some support for the findings.

I
Interest
 High level of interest

The discussions demonstrate a high level of curiosity and focus on personalized breast cancer treatments, showing strong interest.

E
Engagement
 Moderate level of engagement

Participants reference the study and its implications, suggesting a moderate level of in-depth engagement with the topic.

I
Impact
 Moderate level of impact

There is an awareness that this research could influence future treatment strategies, but opinions on its immediate impact are cautious.

Social Mentions

YouTube

1 Videos

Twitter

2 Posts

Metrics

Video Views

11

Total Likes

8

Extended Reach

6,197

Social Features

3

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Predicting Pertuzumab Benefit in HER2 Breast Cancer Using 80-Gene Signature

Predicting Pertuzumab Benefit in HER2 Breast Cancer Using 80-Gene Signature

This episode summarizes a study evaluating the 80Gene Signature's ability to predict benefit from pertuzumab in HER2-positive breast cancer, highlighting the potential for personalized treatment strategies based on tumor subtypes.

ASCO Podcasts

April 3, 2024

11 views

  • JCO Precision Oncology
    @JCOPO_ASCO (Twitter)

    The adjuvant pertuzumab benefit prediction by the 80-gene BluePrint signature in the APHINITY (BIG 4-11) trial. ➡️ https://t.co/V8ddh68GdR @BIGagainstBC @LVVPrint @Agendia #BIGNetwork #APHINITYtrial #bcsm https://t.co/bl1j4z3y38
    view full post

    March 2, 2024

    8

    3

  • alberto ravaioli
    @RavaioliAlberto (Twitter)

    Previsione del beneficio dell'adiuvante Pertuzumab mediante la firma di 80 geni nello studio APHINITY (BIG 4-11) | Oncologia di precisione JCO https://t.co/oAcf7Z8PVQ
    view full post

    January 24, 2024

Abstract Synopsis

  • The study investigated whether the 80Gene Signature (80GS) could predict which early-stage HER2-positive breast cancer patients would benefit most from adding pertuzumab to standard therapy, finding that basal subtype tumors had worse invasive disease-free survival, while HER2 single-activated tumors showed a trend toward greater benefit from pertuzumab.
  • The 80GS classified tumors into luminal, HER2, and basal types, with most luminal tumors showing a single activated pathway, and a significant portion of HER2 and basal tumors showing multiple activated pathways, but no overall difference in survival among subtypes except for the basal single subtype, which had worse outcomes.
  • The findings suggest that the 80GS may help identify specific HER2-positive breast cancer subgroups that are more likely to benefit from dual anti-HER2 therapy with pertuzumab, especially in HER2 single-activated tumors, potentially guiding more personalized treatment strategies.